Skip to content

Xenon Pharmaceuticals Inc.

XENE

CIK 0001582313

← back to feed
Revenue (TTM)
$311K
Q1 May 2026
Net Income (TTM)
−$342.95M
−47.6% YoY Q1 May 2026
EPS Diluted (TTM)
−$4.22
−44.9% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
-120,781.7%
Q1 May 2026
Net Margin
-110,273.6%
Q1 May 2026
Free Cash Flow (TTM)
−$233.72M
Q1 May 2026
Cash
$545.87M
Q1 May 2026
Total Debt
$26.57M
Q1 May 2026
Shares Outstanding
96.67M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings